Validation of the ALFA-1200 model in older patients with AML treated with intensive chemotherapy

,

[1]  A. Gentles,et al.  Clonal architecture predicts clinical outcomes and drug sensitivity in acute myeloid leukemia , 2021, Nature Communications.

[2]  H. Dombret,et al.  Genetic identification of patients with AML older than 60 years achieving long-term survival with intensive chemotherapy. , 2021, Blood.

[3]  G. Borthakur,et al.  Core binding factor acute myelogenous leukemia-2021 treatment algorithm , 2021, Blood Cancer Journal.

[4]  D. Berry,et al.  Association of Measurable Residual Disease With Survival Outcomes in Patients With Acute Myeloid Leukemia: A Systematic Review and Meta-analysis. , 2020, JAMA oncology.

[5]  J. Lindberg,et al.  Integrated transcriptomic and genomic analysis improves prediction of complete remission and survival in elderly patients with acute myeloid leukemia , 2020, Blood Cancer Journal.

[6]  Bob Löwenberg,et al.  Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. , 2017, Blood.

[7]  Inigo Martincorena,et al.  Precision oncology for acute myeloid leukemia using a knowledge bank approach , 2017, Nature Genetics.

[8]  W. Hiddemann,et al.  Spectrum and prognostic relevance of driver gene mutations in acute myeloid leukemia. , 2016, Blood.

[9]  T. Stiewe,et al.  Oncogenic RAS Enables DNA Damage- and p53-Dependent Differentiation of Acute Myeloid Leukemia Cells in Response to Chemotherapy , 2009, PloS one.

[10]  C. Bloomfield,et al.  Patients With Acute Myeloid Leukemia and RAS Mutations Benefit Most From Postremission High-Dose Cytarabine: A Cancer and Leukemia Group B Study , 2008 .